Prolonged Clinical Benefit of Everolimus Therapy in the Management of High-Grade Pancreatic Neuroendocrine Carcinoma

Treatment options for patients with high-grade pancreatic neuroendocrine tumors (pNET) are limited, especially for those with progressive disease and for those who experience treatment failure. Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has been approved for the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Fonseca, Paula J., Uriol, Esther, Galván, José A., Álvarez, Carlos, Pérez, Quionia, Villanueva, Noemi, Berros, José P., Izquierdo, Marta, Viéitez, José M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2013
Materias:
Published online: August, 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764965/
https://www.ncbi.nlm.nih.gov/pubmed/24019785
http://dx.doi.org/10.1159/000354754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764965/
https://www.ncbi.nlm.nih.gov/pubmed/24019785
http://dx.doi.org/10.1159/000354754

Ejemplares similares